Tucson, AZ 的 乳癌 臨床試驗
20 項針對 乳癌 的研究正在 Tucson(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
招募中3 期
- The University of Arizona Cancer Center - North Campus ( Site 0055), Tucson
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
招募中2 期
- The University of Arizona Cancer Center - North Campus, Tucson
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
招募中3 期
- University of Arizona Cancer Center ( Site 0035), Tucson
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
招募中
- University of Arizona Cancer Center, Tucson
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- The University of Arizona Cancer Center - North Campus, Tucson
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- Arizona Clinical Research Center, Inc., Tucson
- University of Arizona Cancer Center, Tucson
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
招募中1/2 期
- University of Arizona Cancer Center, Tucson
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
招募中1/2 期
- University of Arizona, Tucson
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
招募中3 期
- University of Arizona-Cancer Center, Tucson
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
招募中3 期
- Tucson Medical Center HealthCare, Tucson
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Arizona Oncology Associates, Tucson
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
招募中2 期
- University of Arizona Cancer Center - Prevention Research Clinic, Tucson
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
招募中3 期
- University of Arizona - Cancer Center, Tucson
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
招募中1 期
- The University of Arizona Cancer Center, Tucson
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
招募中1 期
- The University of Arizona Cancer Center, Tucson
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)
招募中歡迎健康志工
- University of Arizona, Tucson
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
招募中觀察性研究
- Arizona Oncology Associates, PC - HOPE, Tucson
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
招募中2 期
- Arizona Oncology Associates, Tucson
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
招募中
- University of Arizona, Tucson
CtDNA Based MRD Testing for NAC Monitoring in TNBC
招募中觀察性研究
- Arizona Oncology, Tucson
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
Tucson 的其他研究
- 肥胖症18 項研究
- 非小細胞肺癌17 項研究
- 過重15 項研究
- 轉移性癌症14 項研究
- 癌症(所有類型)12 項研究
- 心血管疾病12 項研究
- 大腸直腸癌11 項研究
- 前列腺癌11 項研究
- 第二型糖尿病11 項研究
- 脂肪性肝病10 項研究
- 心臟衰竭10 項研究
- 高血壓10 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。